Detection of BCR/ABL transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation

Haematologica

Volumn 81, Issue 3, 1996, Pages 201-207

  Santini, Valeria ^a   Zoccolante, Antonella ^a   Bosi, Alberto ^a   Guidi, Stefano ^a   Saccardi, Riccardo ^a   Vannucchi, Alessandro Maria ^a   Martinazzo, Giorgio ^b   Bernabei, Pietro Antonio ^a   Ferrini, Pierluigi Rossi ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Raggio Italgene   (Italy)

Author keywords

Allo BMT; bcr abl; Chronic myeloid leukemia; RT PCR

Indexed keywords

BCR ABL PROTEIN;

ACUTE DISEASE; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COLORIMETRY; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GRAFT VERSUS HOST REACTION; HUMAN; MALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; COLORIMETRY; EVALUATION STUDIES; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA-DIRECTED DNA POLYMERASE; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030322031     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myeloid leukemia: a concise update. Blood 1993; 82:691-703.
2. The Italian Cooperative study Group on Chronic Myeloid Leukemia. Interferon-alpha as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330:820-5.
3. Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104:155-63.
4. Mc Glave P, Batrsch G, Anasetti C, et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the national donor marrow program. Blood 1993; 81:543-50.
5. Marks DJ, Huges TP, Szydlo R, et al. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukemia: influence of GVHD prophylaxis on outcome. Br J Haematol 1992; 81:383-90.
6. Bergamaschi G, Rosti V. Pathogenesis of chronic myeloid leukemia. Haematologica 1994; 79:1-7.
7. Guerrasio A, Martinelli G, Saglio G, et al. Minimal residual disease status in transplanted chronic myelogenous leukemia patients: low incidence of polymerase chain reaction positive cases among 48 long disease-free subjects who received unmanipulated allogenic bone marrow transplants. Leukemia 1992; 6:507-12.
8. van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case of giving donor leukocyte transfusion before the onset of hematological relapse. Blood 1994; 83:3377-83.
9. Martinazzo G, Bichi R, Marcolini S, Peliccia A, Turchetti E. A novel nucleic acid detection system (c-trak) for detecting the t(14,18) and t(9,22) chromosomal translocations associated with hematological malignancies. In: Borden EC, Goldman JM, Grignani F, eds. Molecular diagnosis and monitoring of leukemia and lymphoma. Rome:Ares Serono Symposia publications. Series Challenges in Modern Medicine; 1994; 2:221-39.
10. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidium thiocyanate phenol chloroform extraction. Ann Biochem 1987; 162:156-9.
11. Kwok S, Higuchi R. Avoiding false positive with PCR. Nature 1989; 339:237.
12. Mills KI, Benn P, Birnie GD. Does the breakpoint in the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature. Blood 1991; 78: 1155-61.
13. Jaubert J, Martiat P, Dowding C, Ifrah N, Goldman JM. The position of the M-BCR breakpoint does not predict the duration of the chronic phase or survival in chronic myeloid leukemia. Br J Haematol 1990; 74:30-5.
14. Zaccaria A, Martinelli G, Buzzi M, et al. M-BCR breakpoint location does not predict survival in Philadelphia chromosome-positive chronic myeloid leukemia. Haematologica 1992; 77:16-20.
15. Zaccaria A, Martinelli G, Buzzi M, et al. The type of bcr/abl junction does not predict the survival of patients with Ph1-positive chronic myeloid leukemia. Br J Haematol 1993; 84: 265-8.
16. Gaiger A, Lion T, Kalhs P, et al. Frequent detection of bcr/abl specific mRNA in patients with chronic myeloid leukemia (CML) following allogenic and syngenic bone marrow transplantation (BMT). Leukemia 1993; 7:1766-72.
17. Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the bcr/abl fusion transcript after allogenic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995; 85:2632-8.
18. Lee M, Khouri I, Champlin R, et al. Detection of minimal residual disease by polymerase chain reaction of bcr-abl transcripts in chronic myelogenous leukemia following allogeneic bone marrow transplantation. Br J Haematol 1992; 82:708-14.
19. Verschraegen CF, Talpaz M, Hirsch-Ginsberg CF, et al. Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome positive chronic myeloid leukemia. Blood 1995; 85:2705-10.
20. Thomson JD, Brodsky I, Yunis JJ. Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation. Blood 1992; 79:1629-35.
21. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of bcr-abl transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-36.
22. Arcese W, Mauro FR, Alimena G, et al. Interferon therapy for Ph1 positive CML patients relapsing after T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transpl 1990; 5:309-15.